Joana Sederias

795 total citations
9 papers, 433 citations indexed

About

Joana Sederias is a scholar working on Pulmonary and Respiratory Medicine, Genetics and Oncology. According to data from OpenAlex, Joana Sederias has authored 9 papers receiving a total of 433 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Pulmonary and Respiratory Medicine, 3 papers in Genetics and 3 papers in Oncology. Recurrent topics in Joana Sederias's work include Renal cell carcinoma treatment (3 papers), Glioma Diagnosis and Treatment (2 papers) and Vascular Tumors and Angiosarcomas (1 paper). Joana Sederias is often cited by papers focused on Renal cell carcinoma treatment (3 papers), Glioma Diagnosis and Treatment (2 papers) and Vascular Tumors and Angiosarcomas (1 paper). Joana Sederias collaborates with scholars based in Canada, France and Italy. Joana Sederias's co-authors include Elizabeth A. Eisenhauer, Amit M. Oza, Percy Ivy, Helen Mackay, Jim Biagi, Janet Dancey, Katia Tonkin, Paul Hoskins, Diane Provencher and Prafull Ghatage and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Gynecologic Oncology.

In The Last Decade

Joana Sederias

8 papers receiving 427 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Joana Sederias Canada	6	211	193	136	120	105	9	433
Josep M. del Campo Spain	10	131 0.6×	79 0.4×	261 1.9×	187 1.6×	78 0.7×	20	439
Alison D. Clark United States	5	196 0.9×	114 0.6×	105 0.8×	92 0.8×	34 0.3×	5	370
D-S Bae South Korea	9	130 0.6×	146 0.8×	129 0.9×	72 0.6×	62 0.6×	20	372
Marina Asher United States	8	212 1.0×	199 1.0×	157 1.2×	139 1.2×	201 1.9×	10	560
Nathalie L.G. Sieben Netherlands	8	195 0.9×	70 0.4×	193 1.4×	108 0.9×	50 0.5×	8	433
Rebecca J. Wolsky United States	8	223 1.1×	275 1.4×	216 1.6×	121 1.0×	88 0.8×	21	624
Helena Lagarda Spain	7	162 0.8×	240 1.2×	185 1.4×	95 0.8×	47 0.4×	8	460
Mojca Persic United Kingdom	6	103 0.5×	64 0.3×	167 1.2×	147 1.2×	70 0.7×	12	345
Ingrid Vandenput Belgium	14	140 0.7×	475 2.5×	396 2.9×	105 0.9×	68 0.6×	22	663
Ingirídur Skírnisdóttir Sweden	16	176 0.8×	204 1.1×	499 3.7×	234 1.9×	77 0.7×	26	682

Countries citing papers authored by Joana Sederias

Since Specialization

Citations

This map shows the geographic impact of Joana Sederias's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joana Sederias with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joana Sederias more than expected).

Fields of papers citing papers by Joana Sederias

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joana Sederias. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joana Sederias. The network helps show where Joana Sederias may publish in the future.

Co-authorship network of co-authors of Joana Sederias

This figure shows the co-authorship network connecting the top 25 collaborators of Joana Sederias. A scholar is included among the top collaborators of Joana Sederias based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joana Sederias. Joana Sederias is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

Chu, Quincy S., Maria Carmela Piccirillo, Laurent Greillier, et al.. (2023). IND227 phase III (P3) study of cisplatin/pemetrexed (CP) with or without pembrolizumab (pembro) in patients (pts) with malignant pleural mesothelioma (PM): A CCTG, NCIN, and IFCT trial.. Journal of Clinical Oncology. 41(17_suppl). LBA8505–LBA8505. 18 indexed citations

Lapointe, Sarah, Warren Mason, Mary MacNeil, et al.. (2019). A phase I study of vistusertib (dual mTORC1/2 inhibitor) in patients with previously treated glioblastoma multiforme: a CCTG study. Investigational New Drugs. 38(4). 1137–1144. 31 indexed citations

Seftel, Matthew D., John Kuruvilla, Versha Banerji, et al.. (2016). The CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A Phase II study of the Canadian Cancer Trials Group. Leukemia & lymphoma. 58(6). 1358–1365. 34 indexed citations

Morris, Donald G., Dongsheng Tu, Mustapha Tehfé, et al.. (2016). A Randomized Phase II study of Reolysin in Patients with Previously Treated Advanced or Metatstatic Non Small Cell Lung Cancer (NSCLC) receiving Standard Salvage Chemotherapy – Canadian Cancer Trials Group IND 211.. Journal of Clinical Oncology. 34(15_suppl). e20512–e20512. 5 indexed citations

Dancey, Janet, Monika K. Krzyzanowska, Diane Provencher, et al.. (2015). NCIC CTG IND.206: A phase II umbrella trial of sunitinib (S) or temsirolimus (T) in advanced rare cancers.. Journal of Clinical Oncology. 33(15_suppl). 2594–2594. 2 indexed citations

Hay, Annette E., Irwindeep Sandhu, Vishal Kukreti, et al.. (2014). A Phase II Study of AT9283, an Aurora Kinase Inhibitor, in Patients with Relapased or Refractory Multiple Myloma; NCIC Clinical Trials Group IND.191. Blood. 124(21). 5734–5734.

Pitz, Marshall, Mary MacNeil, David R. Macdonald, et al.. (2012). Phase II study of PX-866 in recurrent glioblastoma.. Journal of Clinical Oncology. 30(15_suppl). 2051–2051. 4 indexed citations

Oza, Amit M., Laurie Elit, Ming‐Sound Tsao, et al.. (2011). Phase II Study of Temsirolimus in Women With Recurrent or Metastatic Endometrial Cancer: A Trial of the NCIC Clinical Trials Group. Journal of Clinical Oncology. 29(24). 3278–3285. 253 indexed citations

Mackay, Helen, Anna V. Tinker, Eric Winquist, et al.. (2009). A phase II study of sunitinib in patients with locally advanced or metastatic cervical carcinoma: NCIC CTG Trial IND.184. Gynecologic Oncology. 116(2). 163–167. 86 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact